| Literature DB >> 27042320 |
Nikmah S Idris1, Michael M H Cheung2, Diederick E Grobbee3, David Burgner4, Nia Kurniati5, Mulyadi M Djer5, Cuno S P M Uiterwaal3.
Abstract
OBJECTIVE: To investigate the effects of HIV infection in children on heart electrical conduction, particularly to delineate the effects of HIV infection from treatment.Entities:
Year: 2016 PMID: 27042320 PMCID: PMC4800758 DOI: 10.1136/openhrt-2015-000340
Source DB: PubMed Journal: Open Heart ISSN: 2053-3624
Figure 1Flow chart of study participant. ART, antiretroviral therapy.
Baseline characteristics of study participants
| Characteristics | ART-naïve HIV n=37 | ART-exposed HIV n=42 | Non-HIV n=50 | p Value |
|---|---|---|---|---|
| Age (years)*, median (range) | 4.8 (0.4–12.5) | 6.1 (1.3–12.2) | 6.4 (2.4–14.0) | 0.22 |
| Male gender, n (%) | 15 (41) | 21 (50) | 23 (46) | 0.70 |
| Low socioeconomic, n (%) | 16 (44) | 25 (60) | 10 (20) | 0.001 |
| Parental smoking after birth, n (%) | ||||
| Mother | 3 (9) | 5 (12) | 0 (0) | 0.05 |
| Father/other household member | 30 (81) | 35 (83) | 33 (66) | 0.11 |
| Parental smoking in pregnancy, n (%) | ||||
| Mother | 6 (18)† | 7 (18) | 1 (2.0) | 0.03 |
| Father/other household member | 29 (78) | 34 (81) | 34 (68) | 0.31 |
| Body weight (kg) | 14.7 (8.2) | 18.8 (5.4) | 22.4 (9.6) | <0.001 |
| Body height (cm) | 99.2 (21.9) | 109.1 (14.0) | 116.3 (17.8) | <0.001 |
| Body mass index (kg/m2) | 14.2 (2.2) | 15.5 (1.9) | 15.9 (2.8) | 0.01 |
| Systolic BP (mm Hg) | 101.6 (10.7) | 99.6 (9.7) | 102.4 (9.7) | 0.41 |
| Diastolic BP (mm Hg) | 63.1 (9.7) | 60.4 (7.5) | 61.3 (7.4) | 0.37 |
| Total cholesterol (mmol/L) | 3.3 (0.9) | 4.5 (0.9) | 4.4 (0.7) | <0.001 |
| LDL cholesterol (mmol/L) | 1.9 (0.7) | 2.6 (0.7) | 2.6 (0.6) | <0.001 |
| HbA1c level | 0.05 (0.04–0.06) | 0.05 (0.04–0.07) | 0.06 (0.04–0.07) | 0.30 |
| hs-CRP, median (range), nmol/L | 36 (0–2759) | 47 (3.7–1227) | 4.7 (0–155) | <0.001‡ |
| HIV clinical stage 3 or 4 | 30 (85.7)§ | 18 (47.4) | <0.001 | |
| CD4 absolute level (n=56) | 258 (8–2716) | 1183 (4–2301) | – | <0.001 |
| CD4% (n=52) | 10 (1–41) | 30 (4–39) | – | 0.001 |
| Viral load (n=19) | 5840 (220–2.0×105) | 185 (0–2.1×106) | ||
| LV EF (%), median (range) | 64.5 (24.8–80.5) | 63.1 (39.3–82.4) | 67.4 (58.6–80.9) | 0.04 |
| LV mass (g) | 41.9 (16.6) | 61.1 (18.6) | 49.8 (17.3) | 0.001 |
| Use of QT prolonging drugs¶ | 16 (43.2) | 20 (34.5) | 0 (0) | |
| ART use in pregnancy, n (%) | 0 (0) | 0 (0) | 0 (0) | |
| Pulse rate (bpm) | 124 (26) | 119 (22) | 115 (19) | 0.14 |
| QTc interval (milliseconds), n=124 | 402.9 (25.7) | 415.0 (23.7) | 388.9 (20.7) | ** |
| PR interval (milliseconds), n=123 | 131.0 (25.4) | 126.1 (24.9) | 122.7 (19.7) | ** |
| QRS interval (milliseconds), n=125 | 68.2 (17.3) | 65.7 (10.5) | 66.1 (11.4) | ** |
†Percentage based on 34 ART-naïve HIV-infected patients.
‡Kruskal-Wallis test.
§Percentage based on 35 ART-naïve HIV-infected patients.
¶Macrolides, trimethoprim, azole antifungals, antihistamine and protease inhibitors.
*Otherwise stated, data is presented as mean (SD). **See table 2 for statistical analysis.
ART, antiretroviral therapy; BP, blood pressure; EF, ejection fraction; HbA1c, glycated haemoglobin; hs-CRP, high-sensitive C reactive protein; LDL, low-density lipoprotein; LV, left ventricular.
Association between HIV infection and cardiac conduction parameters
| QRS interval (milliseconds) | QTc interval (milliseconds) | PR interval (milliseconds) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Model | HIV/treatment group | Mean difference | 95% CI | p Value | Mean difference | 95% CI | Mean difference | 95% CI | p Value | ||
| Crude | Non-HIV | Ref | Ref | Ref | |||||||
| ART-naïve HIV | All 37 | 2.9 | −2.6 to 8.3 | 0.31 | 14.0 | 3.8 to 2.3 | <0.001 | 8.3 | −2.1 to 18.6 | 0.12 | |
| 32 Never ART | 2.5 | −3.2 to 8.1 | 0.39 | 11.5 | 0.4 to 22.5 | 0.04 | 4.7 | −6.1 to 15.5 | 0.39 | ||
| ART-exposed HIV | −0.4 | −5.7 to 4.8 | 0.90 | 26.2 | 16.7 to 35.6 | <0.001 | 3.4 | −6.1 to 12.9 | 0.49 | ||
| RR interval adjustment | Non-HIV | Ref* | |||||||||
| ART-naïve HIV | All 37 | 9.2 | −1.1 to 19.6 | 0.08 | |||||||
| 32 Never ART | 6.7 | −4.3 to 17.5 | 0.23 | ||||||||
| ART-exposed HIV | 4.1 | −5.4 to 13.6 | 0.40 | ||||||||
| Model 1 | Non-HIV | Ref | Ref | Ref† | |||||||
| ART-naïve HIV | All 37 | 4.6 | −0.8 to 10.1 | 0.10 | 16.9 | 6.7 to 27.1 | <0.001 | 10.5 | −0.03 to 21.0 | 0.05 | |
| 32 Never ART | 5.2 | −0.7 to 11.0 | 0.09 | 15.7 | 4.5 to 27.0 | <0.001 | 7.8 | −3.6 to 19.2 | 0.18 | ||
| ART-exposed HIV | 0.1 | −5.0 to 5.2 | 0.97 | 27.1 | 17.8 to 36.3 | <0.001 | 4.2 | −5.3 to 13.9 | 0.42 | ||
| Model 2 | Non-HIV | Ref | Ref‡ | ||||||||
| ART-naïve HIV | All 37 | 5.0 | −1.0 to 11.0 | 0.10 | 18.2 | 7.0 to 29.3 | <0.001 | 12.9 | 2.4 to 23.3 | 0.02 | |
| 32 Never ART | 4.6 | −2.0 to 11.1 | 0.17 | 17.0 | 4.7 to 29.3 | <0.001 | 13.3 | 1.6 to 24.9 | 0.03 | ||
| ART-exposed HIV | 0.2 | −5.1 to 5.5 | 0.94 | 28.9 | 19.3 to 38.5 | <0.001 | 4.3 | −4.7 to 13.3 | 0.35 | ||
Model 1: adjusted for age; model 2: adjusted for age, BMI.
*Adjusted for RR interval.
†Model 1 + adjusted for RR interval.
‡Model 2 + adjusted for RR interval.
ART, antiretroviral therapy; BMI, body mass index.
Figure 2Influence of possible intermediary variables on QTc interval mean difference (95% CI) between HIV-infected (ART-naïve or ART-exposed) children and healthy children. ART, antiretroviral therapy; DBP, diastolic blood pressure; EF, ejection fraction; HbA1c, glycated haemoglobin; hsCRP, high-sensitive C reactive protein; LDL, low-density lipoprotein; LV, left ventricular; SBP, systolic blood pressure.
Figure 3Influence of possible intermediary variables on PR interval mean difference (95% CI) between HIV-infected (ART-naïve or ART-exposed) children and healthy children. ART, antiretroviral therapy; DBP, diastolic blood pressure; EF, ejection fraction; HbA1c, glycated haemoglobin; hsCRP, high-sensitive C reactive protein; LDL, low-density lipoprotein; LV, left ventricular; SBP, systolic blood pressure.
Figure 4QTc interval based on the use of QT-prolonging drugs in HIV-infected children. ART, antiretroviral therapy.